Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Auxilium Pharmaceuticals has released data from the Testim Registry in the United States (TRiUS) which demonstrated the efficacy of Testim 1% (testosterone gel) in improving sexual function in hypogonadal men.
Subscribe to our email newsletter
The data was published in November issue of the Journal of Sexual Medicine.
Testim is a clear topical gel containing 1% testosterone, used to treat adult males who have low or no testosterone.
Investigators assessed data from 271 TRiUS patients and evaluated the correlation between changes in the patients’ Brief Male Sexual Function Inventory (BMSFI) scores and their mean total testosterone levels after 12 months of Testim therapy.
Regression analysis showed that the increased total BMSFI score was associated with increased total testosterone levels.